Susceptibility to multiple sclerosis: Interplay between genes and environment

Current Opinion in Neurology

Volumn 13, Issue 3, 2000, Pages 241-247

  Willer, Cristen J ^a   Ebers, G C ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA;

CHLAMYDOPHILA PNEUMONIAE; DISEASE PREDISPOSITION; ENVIRONMENT; GENE; HUMAN; MULTIPLE SCLEROSIS; PATHOGENESIS; REVIEW;

ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE SCLEROSIS;

EID: 0034043014     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200006000-00002     Document Type: Review

References (97)

1. 1 Ebers GC. Genetic epidemiology of multiple sclerosis. Curr Opin Neurol 1996; 9:155-158.
2. 2 Noseworthy JH. Progress in determining the causes and treatment of multiple sclerosis. Nature 1999; 399(Suppl):A40-A47. An excellent review of both recent and classic studies of clinical symptoms, pathogenesis and treatments.
3. 3 Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999; 67:148-52. This is an excellent paper that follows patients with benign multiple sclerosis for over ten years. Every aspect of the clinical symptoms, onset and disease progession are discussed.
4. 4 Thompson AJ. Benign multiple sclerosis [editorial]. J Neurol Neurosurg Psychiatry 1999; 67:138.
5. 5 Butterfield RJ, Blankenhorn EP, Roper RJ, Zachary JF, Doerge RW, Sudweeks J, et al. Genetic analysis of disease subtypes and sexual dimorphisms in mouse experimental allergic encephalomyelitis (EAE): relapsing/remitting and monophasic remitting/nonrelapsing EAE are immunogenetically distinct. J Immunol 1999; 162:3096-3102. It is suggested that the human multiple sclerosis subtypes may be controlled by modifier genes.
6. 6 Compston A. The genetic epidemiology of multiple sclerosis. Philos Trans R Soc Lond B Biol Sci 1999; 354:1623-1634. Family studies in multiple sclerosis and strategies to identify susceptibility genes are reviewed.
7. 7 Brassat D, Azais-Vuillemin C, Yaouanq J, Semana G, Reboul J, Cournu I, et al. Familial factors influence disability in MS multiplex families. French Multiple Sclerosis Genetics Group. Neurology 1999; 52:1632-1636. Studies assessing inheritance of clinical features may help dissect susceptibility to multiple sclerosis.
8. 8 Kurtzke JF, Beebe GW, Norman Jr JE. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 1979; 29:1228-1235.
9. 9 Visscher BR, Detels R, Coulson AH, Malmgren RM, Dudley JP. Latitude, migration, and the prevalence of multiple sclerosis. Am J Epidemiol 1977; 106:470-475.
10. 10 Baum HM, Rothschild BB. The incidence and prevalence of reported multiple sclerosis. Ann Neurol 1981; 10:420-428.
11. 11 Rosati G. Descriptive epidemiology of multiple sclerosis in Europe in the 1980s: a critical overview. Ann Neurol 1994; 36 (Suppl 2):S164-S174.
12. 12 Miller DH, Hammond SR, McLeod JG, Purdie G, Skegg DC. Multiple sclerosis in Australia and New Zealand: are the determinants genetic or environmental? [see comments]. J Neurol Neurosurg Psychiatry 1990; 53:903-905.
13. 13 McLeod JG, Hammond SR, Hallpike JF. Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results. Med J Aust 1994; 160:117-122.
14. 14 Hogancamp WE, Rodriguez M, Weinshenker BG. The epidemiology of multiple sclerosis. Mayo Clin Proc 1997; 72:871-878.
15. 15 Hernan MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999; 53:1711-1718. A thorough study of incidence in multiple sclerosis. It is interesting how the incidence gradient changes over time.
16. 16 Sadovnick AD, Dircks A, Ebers GC. Genetic counselling in multiple sclerosis: risks to sibs and children of affected individuals. Clin Genet 1999; 56:118-122.
17. 17 Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group [see comments]. Nature 1995; 377:150-151.
18. 18 Sadovnick AD, Ebers GC, Dyment DA, Risch NJ. Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. Lancet 1996; 347:1728-1730.
19. 19 Risch N. Linkage strategies for genetically complex traits. I. Multilocus models [see comments]. Am J Hum Genet 1990; 46:222-228.
20. 20 Sadovnick AD, Armstrong H, Rice GP, Bulman D, Hashimoto L, Paty DW, et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993; 33:281-285.
21. 21 Sadovnick AD. Familial recurrence risks and inheritance of multiple sclerosis. Curr Opin Neurol Neurosurg 1993; 6:189-194.
22. 22 Goodman L. The human genome project aims for 2003. Genome Res 1998; 8:997-999.
23. 23 Tsui LC, Durie P. Genotype and phenotype in cystic fibrosis. Hosp Pract (Off Ed) 1997; 32:115-118, 123-9, 134, passim.
24. 24 Lunkes A, Trottier Y, Mandel JL. Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases. Essays Biochem 1998; 33:149-63.
25. 25 Thomson G, Esposito MS. The genetics of complex diseases. Trends Cell Biol 1999; 9:M17-M20. Discussion of techniques utilized for identifying genes involved in Mendelian traits and the application to complex traits.
26. 26 Risch N. Linkage strategies for genetically complex traits. II. The power of affected relative pairs [see comments]. Am J Hum Genet 1990; 46:229-241.
27. 27 Sorensen TL, Ransohoff RM. Etiology and pathogenesis of multiple sclerosis. Semin Neurol 1998; 18:287-294.
28. 28 Ebers G. Modelling multiple sclerosis [news; comment]. Nat Genet 1999; 23:258-259.
29. 29 Gold I, Hartung I, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 2000; 6:88-91.
30. 30 Martino G, Hartung HP. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr Opin Neurol 1999; 12:309-321. The molecular aspects of T cells and their potential role in multiple sclerosis pathogenesis are discussed.
31. 31 Gran B, Hemmer B, Vergelli M, McFarland HF, Martin R. Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity. Ann Neurol 1999; 45:559-567. An interesting hypothesis about T cell immunology and multiple sclerosis.
32. 32 Tuohy VK, Yu M, Yin L, Kawczak JA, Kinkel PR. Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J Autoimmun 1999; 13:11-20.
33. 33 Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 2000; 403:216-220. Cbl-b knock out mice and the immunological consequences are investigated thoroughly in this paper.
34. 34 Waxman SG. Multiple sclerosis as a neuronal disease. Arch Neurol 2000; 57:22-24. A discussion of axonal pathology and its potential role in multiple sclerosis.
35. 35 McFarland HF. The path to damage in multiple sclerosis [editorial]. Ann Neurol 1999; 46:141-142.
36. 36 Silber E, Sharief MK. Axonal degeneration in the pathogenesis of multiple sclerosis. J Neurol Sci 1999; 170:11-18. This paper raises questions about the causes and effects of axonal damage.
37. 37 Gonzalez-Scorano F, Rima B. Infectious etiology in multiple sclerosis: the debate continues. Trends Microbiol 1999; 7:475-477.
38. 38 Hafler DA. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J Clin Invest 1999; 104:527-529. A discussion of potential causes of epitope spreading.
39. 39 Dyment DA, Sadovnick AD, Ebers GC. Genetics of multiple sclerosis. Hum Mol Genet 1997; 6:1693-1698.
40. 40 Sawcer S, Goodfellow PN. Inheritance of susceptibility to multiple sclerosis. Curr Opin Immunol 1998; 10:697-703.
41. 41 Schmidt S. Candidate autoantigens in multiple sclerosis. Mult Scler 1999; 5:147-60. The plausibility of T cell pathway genes and myelin related proteins as candidates is discussed.
42. 42 Ridgway WM, Fasso M, Fathman CG. A new look at major histocompatibility and autoimmune disease. Science 1999; 284:749-751. A brief review of important aspects of the molecular action of major histocompatibility and its relation to diabetes and nod mice.
43. 43 Hillert J. Human leukocyte antigen studies in multiple sclerosis. Ann Neurol 1994; 36(Suppl):S15-S17.
44. 44 Allcock RJ, de la Concha EG, Femandez-Arquero M, Vigil P, Conejero L, Arroyo R, et al. Susceptibility to multiple sclerosis mediated by HLA-DRB1 is influenced by a second gene telomeric of the TNF cluster. Hum Immunol 1999; 60:1266-1273. An interesting look at which locus within the human leukocyte antigen is responsible for the known DR2 association with multiple sclerosis.
45. 45 Fernandez-Arquero M, Arroyo R, Rubio A, Martin C, Vigil P, Conejero L, et al. Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis. Neurology 1999; 53:1361-1363.
46. 46 Maurer M, Kruse N, Giess R, Kyriallis K, Toyka KV, Rieckmann P. Gene polymorphism at position -308 of the tumor necrosis factor alpha promoter is not associated with disease progression in multiple sclerosis patients. J Neurol 1999; 246:949-954.
47. 47 Trojano M, Liguori M, De Robertis F, Stella A, Guanti G, Avolio C, et al. Comparison of clinical and demographic features between affected pairs of Italian multiple sclerosis multiplex families; relation to tumour necrosis factor genomic polymorphisms. J Neurol Sci 1999; 162:194-200. Interesting results that need confirmation in a larger dataset.
48. 48 Sotgiu S, Pugliatti M, Serra C, Rosati G, Dolei A, Marrosu MG. Tumor necrosis factor 2 allele does not contribute to increased tumor necrosis factor-alpha production in Sardinian multiple sclerosis. Ann Neurol 1999; 46:799-800.
49. 49 Ma JJ, Nishimura M, Mine H, Saji H, Ohta M, Saida K, et al. HLA-DRB1 and tumor necrosis factor gene polymorphisms in Japanese patients with multiple sclerosis. J Neuroimmunol 1998; 92:109-112.
50. 50 Harbo HF, Celius EG, Vartdal F, Spurkland A. CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens 1999; 53:106-110.
51. 51 Ligers A, Xu C, Saarinen S, Hillert J, Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol 1999; 97:182-190.
52. 52 Fukazawa T, Yanagawa T, Kikuchi S, Yabe I, Sasaki H, Hamada T, et al. CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients. J Neurol Sci 1999; 171:49-55.
53. 53 Reboul J, Mertens C, Levillayer F, Eichenbaum-Voline S, Vilkoren T, Cournu I, et al. Cytokines in genetic susceptibility to multiple sclerosis: a candidate gene approach. French Multiple Sclerosis Genetics Group. J Neuroimmunol 2000; 102:107-112. Candidate gene approaches may be of particular value in the next few years of multiple sclerosis genetics research.
54. 54 Sciacca FL, Ferri C, Vandenbroeck K, Veglia F, Gobbi C, Martinelli F, et al. Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology 1999; 52:1896-1898.
55. 55 Chataway J, Sawcer S, Sherman D, Hobart M, Fernie B, Coraddu F, et al. No evidence for association of multiple sclerosis with the complement factors C6 and C7. J Neuroimmunol 1999; 99:150-156.
56. 56 Pickard C, Mann C, Sinnott P, Boggild M, Hawkins C, Strange RC, et al. Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis. J Neuroimmunol 1999; 101:207-210.
57. 57 Shields DC, Schaecher KE, Saido TC, Banik NL. A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci USA 1999; 96:11486-11491. An interesting novel candidate gene.
58. 58 Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 2000; 403:211-216. The counterpart of [33•].
59. 59 Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, Poliani PL, et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol 2000; 30:498-508.
60. 60 Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Hamada T, Miyasaka K, et al. Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci 1999; 166:47-52. Interesting to see whether associations found in Japanese patients can be confirmed in Northern European patients.
61. 61 Steckley JL, Dyment DA, Sadovnick AD, Risch N, Hayes C, Ebers GC, et al and the Canadian Collaborative Study Group. Genetic analysis of vitamin D related genes in Canadian multiple sclerosis genes. Neurology 2000; 54:729-732.
62. 62 Chataway J, Sawcer S, Feakes R, Coraddu F, Broadley S, Gray J, et al. More evidence that founder effects exist in the European population [letter]. Eur J Hum Genet 1999; 7:623-624.
63. 63 Strunk T, Bubel S, Mascher B, Schlenke P, Kirchner H, Wandinger KP. Increased numbers of CCR5+ interferon-gamma- and tumor necrosis factor-alpha-secreting T lymphocytes in multiple sclerosis patients. Ann Neurol 2000; 47:269-73.
64. 64 Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 1997; 58:52-69.
65. 65 Oliveri RL, Cittadella R, Sibilia G, Manna I, Valentine P, Gambardella A, et al. APOE and risk of cognitive impairment in multiple sclerosis. Acta Neurol Scand 1999; 100:290-295.
66. 66 Evangelou N, Jackson M, Beeson D, Palace J. Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 67:203-205.
67. 67 Chataway J, Sawcer S, Feakes R, Coraddu F, Broadley S, Jones HB, et al. A screen of candidates from peaks of linkage: evidence for the involvement of myeloperoxidase in multiple sclerosis. J Neuroimmunol 1999; 98:208-213. A thorough analysis of a number of candidate genes, integrating genome scans and candidate gene methodologies.
68. 68 Zouali H, Faure-Delanef L, Lucotte G. Chromosome 19 locus apolipoprotein C-ll association with multiple sclerosis. Mult Scler 1999; 5:134-136.
69. 69 Sawcer S, Jones HB, Feakes R, Gray J, Smaldon N, Chataway J, et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996; 13:464-468.
70. 70 Kuokkanen S, Gschwend M, Rioux JD, Daly MJ, Terwilliger JD, Tienari PJ, et al. Genomewide scan of multiple sclerosis in Finnish multiplex families. Am J Hum Genet 1997; 61:1379-1387.
71. 71 Haines JL, Ter-Minassian M, Bazyk A, Gusella JF, Kim DJ, Terwedow H, et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatabitity complex. The Multiple Sclerosis Genetics Group [see comments]. Nat Genet 1996; 13:469-471.
72. 72 Ebers GC, Kukay K, Bulman DE, Sadovnick AD, Rice G, Anderson C, et al. A full genome search in multiple sclerosis [see comments]. Nat Genet 1996; 13:472-476.
73. 73 Multiple Sclerosis Genetics Group. Clinical demographics of multiplex families with multiple sclerosis. Ann Neurol 1998; 43:530-534.
74. 74 Kalman B, Alder H. Is the mitochondrial DNA involved in determining susceptibility to multiple sclerosis? Acta Neurol Scand 1998; 98:232-237.
75. 75 Heales SJ, Bolanos JP, Stewart VC, Brookes PS, Land JM, Clark JB. Nitric oxide, mitochondria and neurological disease. Biochim Biophys Acta 1999; 1410:215-228. Discussion of the involvement of the mitochondrial respiratory chain in the pathogenesis of neurological diseases such as Alzheimer's, and multiple sclerosis.
76. 76 Kalman B, Li S, Chatterjee D, O'Connor J, Voehl MR, Brown MD, el al. Large scale screening of the mitochondrial DNA reveals no pathogenic mutations but a haplotype associated with multiple sclerosis in Caucasians. Acta Neurol Scand 1999; 99:16-25.
77. 77 Gulwani-Akolkar B, Shi B, Akolkar PN, Ito K, Bias WB, Silver J. Do HLA genes play a prominent role in determining T cell receptor V alpha segment usage in humans? J Immunol 1995; 154:3843-3851.
78. 78 Michalowska-Wender G, Nowak J, Losy J, Januszkiewicz D, Wender M. Diversity of V delta-J delta gene rearrangement in peripheral blood lymphocytes and intrathecal IgG synthesis in multiple sclerosis. Folia Neuropathol 1999; 37:113-116.
79. 79 Utz U, Biddison WE, McFarland HF, McFarlin DE, Flerlage M, Martin R. Skewed T-cell receptor repertoire in genetically identical twins correlates with multiple sclerosis [see comments]. Nature 1993; 364:243-247.
80. 80 Haegert DG, Cowan T, Murray TJ, Gadag V, O'Connor P. Does a shift in the T-cell receptor repertoire precede the onset of MS? Neurology 1999; 53:485-490.
81. 81 Meinl E. Concepts of viral pathogenesis of multiple sclerosis. Curr Opin Neurol 1999; 12:303-307. Mainly a discussion of HHV-6 and multiple sclerosis associated retrovirus.
82. 82 Bergstrom T. Herpesviruses - a rationale for antiviral treatment in multiple sclerosis. Antiviral Res 1999; 41:1-19. Proposed models of pathogenesis and a potential treatment are linked.
83. 83 Ongradi J, Rajda C, Marodi CL, Csiszar A, Vecsei L. A pilot study on the antibodies to HHV-6 variants and HHV-7 in CSF of MS patients. J Neurovirol 1999; 5:529-532.
84. 84 Friedman JE, Lyons MJ, Cu G, Ablashl DV, Whitman JE, Edgar M, et al. The association of the human herpesvirus-6 and MS. Mult Scler 1999; 5:355-362.
85. 85 Ablashi DV, Lapps W, Kaplan M, Whitman JE, Richert JR, Pearson GR. Human Herpesvirus-6 (HHV-6) infection in multiple sclerosis: a preliminary report. Mult Scler 1998; 4:490-496.
86. 86 Rotola A, Cassai E, Tola MR, Granieri E, Di Luca D. Human herpesvirus 6 is latent in peripheral blood of patients with relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 67:529-531.
87. 87 Goldberg SH, Albright AV, Lisak RP, Gonzalez-Scarano F. Polymerase chain reaction analysis of human herpesvirus-6 sequences in the sera and cerebrospinal fluid of patients with multiple sclerosis. J Neurovirol 1999; 5:134-139.
88. 88 Mirandola P, Stefan A, Brambilla E, Campadelli-Fiume G, Grimaldi LM. Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients. Neurology 1999; 53:1367-1368.
89. 89 Stratton CW, Mitchell WM, Sriram S. Does Chlamydia pneumoniae play a role in the pathogenesis of multiple sclerosis? [editorial]. J Med Microbiol 2000; 49:1-3.
90. 90 Gilden DH. Chlamydia: a role for multiple sclerosis or more confusion? Ann Neurol 1999; 46:4-5. A brief review of Chlamydia studies in multiple sclerosis research.
91. 91 Sriram S, Stratton CW, Yao S, Tharp A, Ding L, Bannan JD, et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999; 46:6-14.
92. 92 Boman J, Roblin PM, Sundstrom P, Sandstrom M, Hammerschlag MR. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 2000; 54:265-266.
93. 93 Fujinami RS, Libbey JE. Endogenous retroviruses: are they the cause of multiple sclerosis? Trends Microbiol 1999; 7:263-264.
94. 94 Lavi E, Schwartz T, Jin YP, Fu L. Nidovirus infections: experimental model systems of human neurologic diseases. J Neuropathol Exp Neurol 1999; 58:1197-206.
95. 95 Ross RT, Cheang M, Landry G, Klassen L, Doerksen K. Herpes zoster and multiple sclerosis. Can J Neurol Sci 1999; 26:29-32. A large-scale epidemiological approach to answering questions of viruses in multiple sclerosis.
96. 96 Summers BA, Appel MJ. Aspects of canine distemper virus and measles virus encephalomyelitis. Neuropathol Appl Neurobiol 1994; 20:525-534.
97. 97 Munch M, Hvas J, Christensen T, Moller-Larsen A, Haahr S. The implications of Epstein-Barr virus in multiple sclerosis - a review. Acta Neurol Scand Suppl 1997; 169:59-64.